Association of fenofibrate and diabetic retinopathy in type 2 diabetic patients: A population-based retrospective cohort study in taiwan

Keyphrases

• Adjusted Hazard Ratio 25%
• Angiotensin Receptor Blockers 12%
• Angiotensin-converting Enzyme Inhibitor (ACEi) 12%
• Anticoagulant Agents 12%
• Charlson Comorbidity Index 12%
• Cox Proportional Hazards Regression Analysis 12%
• Diabetes 12%
• Diabetic Retinopathy 100%
• Fenofibrate 100%
• Frequent Use 12%
• Gemfibrozil 12%
• Group-based 12%
• Hazard Ratio 25%
• Hypertension 12%
• Hypoglycemic Activity 12%
• Laser Therapy 37%
• New Onset 12%
• No Significant Difference 12%
• Placebo Groups 12%
• Population-based Cohort Study 12%
• Population-based Retrospective Cohort Study 100%
• PPAR Agonists 12%
• Retinopathy 37%
• Statins 12%
• Taiwan 100%
• Type 2 Diabetic Patients 100%

Pharmacology, Toxicology and Pharmaceutical Science

• Angiotensin Receptor Antagonist 12%
• Anticoagulant Agent 12%
• Antidiabetic Agent 12%
• Cohort Study 100%
• Comorbidity 12%
• Diabetes Mellitus 100%
• Diabetic Retinopathy 100%
• Dipeptidyl Carboxypeptidase Inhibitor 12%
• Fenofibrate 100%
• Gemfibrozil 12%
• Hydroxymethylglutaryl Coenzyme A Reductase Inhibitor 12%
• Placebo 12%
• PPAR Agonist 12%
• Retinopathy 37%

Neuroscience

• ACE Inhibitor 12%
• Angiotensin Receptor 12%
• Comorbidity 12%
• Diabetes Mellitus 100%
• Diabetic Retinopathy 100%
• Fenofibrate 100%
• Gemfibrozil 12%
• Placebo 12%
• PPAR Agonist 12%
• Retinal Disease 37%
• Statin 12%